(Q34745772)

4 August 2017

title

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients (English)

1 reference

4 August 2017

1 reference

S R Park

1

1 reference

4 August 2017

S-Y Kong

2

1 reference

4 August 2017

B-H Nam

3

1 reference

4 August 2017

I J Choi

4

1 reference

4 August 2017

C G Kim

5

1 reference

4 August 2017

J Y Lee

6

1 reference

4 August 2017

S J Cho

7

1 reference

4 August 2017

Y W Kim

8

1 reference

4 August 2017

K W Ryu

9

1 reference

4 August 2017

J H Lee

10

1 reference

4 August 2017

J Rhee

11

1 reference

4 August 2017

Y-I Park

12

1 reference

4 August 2017

N K Kim

13

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

British Journal of Cancer

4 August 2017

published in

1 reference

4 August 2017

volume

104

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

1126-1134

1 reference

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

National cancer incidence for the year 2002 in Korea

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Global cancer statistics, 2002

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

Association of an ERCC1 polymorphism with adult-onset glioma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068488

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Nicotine metabolism and CYP2A6 allele frequencies in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

ERCC1 and clinical resistance to platinum-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.24

Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro

21 January 2018

1 reference

12 December 2020

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes

1 reference

12 December 2020

Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.24

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference